About 10%-15% of pheochromocy tomas eventually develop metastases (1) . Few patients with metastatic pheo chromocytoma are suitable candidates for surgical resection of the tumor.
This correspondence introduces radiofrequency ablation (RFA) as an alternate treatment modality in pheo chromocytoma. RFA is a safe, predict able, and effective method for lo cal tumor destruction in primary and metastatic carcinomas (2) (3) (4) (5) (6) (7) . We report on a patient with metastatic pheo chromocytoma with a rapidly growing bone metastasis who was treated with RFA.
The patient, a 42-year-old man, first presented with episodes of hematuria, hypertension, and palpitations. A 24 hour urine collection demonstrated el evated levels of catecholamines and metanephrines. Computed tomography (CT) scan revealed a 5.5 × 7.5 × 8.0-cm pheochromocytoma invading the poste rior urinary bladder wall. His tumor was considered unresectable. The patient was treated with radiotherapy and six cycles of chemotherapy, with 80% tu mor shrinkage followed by cystectomy. CT scans 5 years later showed lung metastases and a 0.5-cm third lesion on the right rib. The lesion grew gradually, then rapidly to 3 cm in diameter, with marked elevations in the levels of plasma norepinephrine (6974 pg/mL), free normetanephrine (3516 pg/mL), urinary norepinephrine (707 μg/24 hours), total metanephrines (6090 μg/24 hours), and vanillylmandelic acid (18.2 μg/24 hours). 6-[
18 F]Fluorodopamine positron emission tomography ( Fig. 1 ) and [
131 I]metaiodobenzylguanidine scintigraphy confirmed that the rib lesion was metastatic pheochromocy toma. To treat the rib lesion, we chose RFA after we considered the limitations, side effects, and time commitments of radiotherapy, chemotherapy, and sur gical resection. Because RFA disrupts cells by heat, marked catecholamine release was anticipated. Therefore, be ginning 2 weeks before the proce dure, the patient received phenoxyben zamine, atenolol, and α-methyl-para tyrosine (Demser™; Merck Sharp & Dohme, West Point, PA). The ad equacy of the adrenergic blockade was assessed by a provocative glucagon test 2 days before the RFA. Glucagon in creased the patient's blood pressure, and phenoxybenzamine was increased to 80 mg and Demser™ to 1.5 g once a day.
RFA was performed in the interven tional CT scan suite after an intercostal nerve block. Probe temperature was gradually increased to 86 °C, with treat ment duration progressively increasing from 10 seconds to 10 minutes. RFA resulted in marked norepinephrine release (0.24-2.78 pmol/mL) and hyper tension, managed with intravenous labetelol and a nitroprusside infusion. After RFA, phenoxybenzamine and Demser™ were tapered over a 2-week D) CT scan of the chest during treatment shows the unin sulated tip (arrow) of the radiofrequency needle electrode in the mass, after being placed with CT and ultrasound guidance. E) T-2 weighted magnetic resonance image 6 weeks after treatment shows low signal in region of mass, with uniform and regular, high signal in the periphery, consistent with inflammatory granulation tissue. Consistent with the absence of blood flow, the tumor did not enhance following contrast admin istration after treatment (not shown). F) Contrast-enhanced CT scan of the chest 6 weeks after treatment shows lack of enhancement in the region of the tumor, suggesting successful ablation on early follow-up. Arrow points to the area where the tumor was originally found.
period. Successful ablation was docu mented by loss of signal intensity on CT and lack of tumor enhancement on mag netic resonance imaging, 1 day and 6 weeks after RFA (Fig. 1) , and by 6-[
18 F]fluorodopamine positron emis sion tomography scan 2 weeks after RFA (Fig. 1) .
This case illustrates that RFA can be used safely to ablate rapidly growing pheochromocytoma. In pheochromocy toma, where cells release contents in re sponse to stimuli, it was unclear whether RFA would be safe. However, oral phe noxybenzamine, atenolol, and Dem ser™ with intravenous labetelol and nitroprusside provided adequate control of acute hypertension. On the basis of this experience, we propose that RFA be evaluated further in patients with pri mary or metastatic pheochromocytoma as an alternative to surgery, chemo therapy, or radiotherapy. 6-[
18 F]Fluo rodopamine positron emission tomogra phy scan provides a valuable tool to evaluate the effects of the ablation; it can be used as an alternative to CT and magnetic resonance imaging, in con junction with measurements of levels of plasma catecholamines and metaneph rines.
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